Drug Profile
Ciclosporin ophthalmic - Novaliq
Alternative Names: 0.1% cyclosporin A; CyclASol 0.1%; Cyclosol; Cyclosporine; Cyclosporine-A; SHR-8028; VEVYELatest Information Update: 19 Feb 2024
Price :
$50
*
At a glance
- Originator Novaliq
- Developer Jiangsu Hengrui Medicine Co.; Novaliq
- Class Anti-inflammatories; Antineoplastics; Antipsoriatics; Antirheumatics; Ciclosporins; Eye disorder therapies; Heart failure therapies; Neuroprotectants
- Mechanism of Action Calcineurin inhibitors; Immunomodulators; Mitochondrial permeability transition pore inhibitors; P-glycoprotein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Marketed Dry eyes
- Research Hypersensitivity